Cite
HARVARD Citation
Catenacci, D. et al. (n.d.). Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet oncology. 18 (11), pp. 1467-1482. [Online].